Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy  ± Trastuzumab in Locally Advanced Breast Cancer

CONCLUSION: Women with ER+/HER2- disease are the least likely to achieve pCR, with the highest rates in HER2+ and triple-negative subgroups. Degree of response is associated with OS; despite the comparatively higher likelihood of achieving pCR in ER-/HER2+ and triple-negative, these subgroups experience a survival detriment. We are consistent with the published data that patients who attain the pathological complete response defined as ypT0/ypN0 have improved outcomes.PMID:33628241 | PMC:PMC7895557 | DOI:10.1155/2021/6639763

Source: Journal of Oncology - February 25, 2021 Category: Cancer & Oncology Authors: Taher Al-Tweigeri Mahmoud Elshenawy Ahmed Badran Ayman Omar Kausar Suleman Osama Al Malik Ihab Anwar Noha Jastaniya Asma Tulbah Mohammad Al Shabanah Dahish Ajarim Adher Al Sayed Source Type: research